SELANK

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, the natural immune-modulating tetrapeptide. It is approved in Russia as an anxiolytic and cognitive enhancement agent, marketed under the trade name Selank-S Pharm, and has been used clinically for generalized anxiety disorder and adaptation disorders. Selank is distinguished from other anxiolytics by producing anxiolytic effects without sedation, drug dependence, or withdrawal symptoms. Regulatory note: Selank was withdrawn from the FDA's Category 2 bulk substances list in September 2024 (an earlier round than the April 2026 removals affecting Semax and others).

What is Selank and how does the tuftsin-derived anxiolytic mechanism work?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin (Thr-Lys-Pro-Arg) with C-terminal extensions for stability, proposed to act through multiple mechanisms: GABA neurotransmitter system modulation, serotonergic effects, immune system modulation (reflecting the tuftsin origin), and effects on BDNF and neurotransmitter receptor expression. Unlike benzodiazepines, Selank produces anxiolytic effects without sedation, motor impairment, or dependence liability — a distinctive profile that drove its Russian clinical approval.

Evidence level: approved in Russia (anxiety disorders); preclinical extensive (anxiolytic, immune effects); Russian clinical trials; no Western RCT

What does the research show for Selank?

Russian clinical practice has used Selank for generalized anxiety disorder, adaptation disorders, and stress-related conditions, with controlled clinical trials in Russian research contexts supporting the approved use. Preclinical work has demonstrated anxiolytic effects across multiple rodent anxiety models, effects on neurotransmitter receptor expression, and immune-modulating effects consistent with the tuftsin origin. No Western Phase 2/3 randomized controlled trial of Selank has been published as of August 2026; the controlled-trial evidence is entirely from Russian clinical research, which is a single-country evidence base that Western regulators have not independently evaluated.

Evidence level: approved Russian clinical use; Russian clinical trials; preclinical extensive; no Western RCT

How does Selank compare to Semax and other Russian neuropeptides?

Selank and Semax are the two flagship Russian-approved neuropeptide nootropics with distinct mechanism and indication profiles — Selank for anxiolytic effects, Semax for cognitive enhancement and neuroprotection. See the head-to-head Semax vs Selank comparison for mechanism, evidence, and identity-verification differences.

What are the documented side effects of Selank?

Side effects in Russian clinical use are mild — occasional mild irritation of nasal mucosa with intranasal administration, transient headache, and rare reports of mild stimulation effects. A distinguishing feature is the absence of sedation, dependence, or withdrawal effects associated with benzodiazepines and other GABA-modulating anxiolytics. Long-term safety has been observed in Russian clinical practice over decades.

Evidence level: russian clinical safety record (decades); no Western RCT safety data

What is the regulatory status of Selank?

Selank is approved for medical use in Russia for anxiety disorders, but is not approved by the FDA, EMA, or other major Western regulators. Selank has no FDA compounding pathway. Its nomination (as selank acetate, code TP-7) to the FDA's 503A bulk drug substances list was withdrawn by the nominator, so on the FDA's current bulk-substances page — last updated April 2026 — selank acetate appears in the "nominated but withdrawn" table rather than on the active Category 2 list, and it was not among the twelve peptides the FDA removed from Category 2 in April 2026. It is not on the Category 1 list eligible for compounding, and the FDA notes it "lacks important information regarding any safety issues raised by selank acetate administered to humans." Current status in FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Selank vendor verification matter?

Selank synthesis is mature and widely available in the research-grade market, with quality variance across vendors and occasional mislabeling with related tuftsin-derived peptides. Mass spectrometry identity confirmation distinguishes Selank from related heptapeptides. Intranasal formulations have additional stability and excipient considerations not addressed by basic peptide HPLC. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Selank vendors?

Peptigrity collects independent third-party Certificates of Analysis for Selank from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Selank do?

Selank is approved in Russia for anxiolytic effects without sedation, drug dependence, or withdrawal symptoms — a distinctive profile compared to benzodiazepines. Russian clinical practice has used Selank for generalized anxiety disorder and adaptation disorders. Western Phase 2/3 RCT evidence is more limited.

Is Selank legal to purchase?

Selank is approved for medical use in Russia and is legal to purchase as a research chemical for laboratory use in most other jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Does Selank cause dependence like benzodiazepines?

Available evidence from Russian clinical use and preclinical studies indicates Selank does not produce dependence, tolerance, or withdrawal effects characteristic of benzodiazepines. The distinct mechanism (multiple neurotransmitter system modulation rather than direct GABA-A receptor agonism) appears to underlie this difference. Long-term Western-standard safety data remains limited.

How does Selank compare to Semax?

Selank is the anxiolytic of the Russian neuropeptide pair; Semax is the cognitive enhancement and neuroprotection compound. Different mechanisms (tuftsin-derived vs. ACTH-derived), different primary effects, different Russian-approved indications.

How can I verify a Selank vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Selank dose?

No. Peptigrity is an independent review platform, not a medical authority. Russian clinical protocols vary by indication; intranasal dosing is the primary clinical route. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Selank is approved for medical use in Russia but is not approved by the FDA or other major Western regulators. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.